RxDoctor Payments DataLook up a doctor →

Tiffany Dellinger, NP

Nurse Practitioner · Mount Pleasant, SCNPI 1164077715

Payments from drug & device makers

$8,981in general payments, 2019–2025

Across 472 payments — averaging $19.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$1K
  • Novo Nordisk$1K
  • AbbVie$868
  • Amgen$691
  • Lilly USA, LLC$648
  • Sumitomo Pharma America, Inc.$447
  • plus $4K from 40 others

What the payments were for

  • Speaking & faculty fees$340%
  • Food & beverage$8,947100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,981 in reported general payments places this provider in the 95th percentile of 1,346 nurse practitioner providers in South Carolina.

See all nurse practitioner providers in South Carolina

Medicare billing

Part B allowed, 2024
$44,661
Medicare patients
336
Services billed
911

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban29$31,242
OzempicSemaglutide24$26,312
MounjaroTirzepatide14$14,649
MyrbetriqMirabegron23$14,196
Atorvastatin Calcium148$2,197
Omeprazole103$1,888
Albuterol Sulfate HfaAlbuterol Sulfate52$1,714
Olmesartan Medoxomil35$1,512
Levothyroxine Sodium116$1,458
Losartan Potassium86$1,243
Gabapentin78$1,129
Escitalopram Oxalate54$1,118
Tamsulosin Hcl56$1,054
Rosuvastatin Calcium82$1,007
Bupropion XlBupropion Hcl28$936

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$1,297$31,24229 claims
Novo NordiskOzempic$1,061$26,31224 claims
Lilly USA, LLCMounjaro$648$14,64914 claims
Astellas Pharma US IncMyrbetriq$198$14,19623 claims
Almatica Pharma LLCSertraline Hcl$28$64729 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,346 nurse practitioner providers in South Carolina.

Other nurse practitioner in Mount Pleasant

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →